Risky business: target choice in adoptive cell therapy
نویسندگان
چکیده
منابع مشابه
astases with Adoptive Cell Therapy
ownloade pose: To determine the objective response rate and response duration of melanoma brain metaso adoptive cell therapy (ACT) with autologous antitumor lymphocytes plus interleukin-2 following phodepleting preparative regimen. hods: Between 2000 and 2009, 264 patients with metastatic melanoma received ACT, consisting of hosphamide and fludarabine with or without total body irradiation, fol...
متن کاملRisky business.
In prior studies by high-level commissions, emphasis was given to improving the scientific basis and institutional procedures for risk assessment and risk regulation within existing statutory frameworks. Recommendations have led to slow but steady progress. This study is considerably different. It emphasizes a public health approach for efficient use of resources in a new flexible framework for...
متن کاملRisky business.
With the establishment of the National Center for Advanced Translational Sciences (NCATS) in December of 2011, the National Institutes of Health (NIH) and the US government made a commitment to directly invest in translational research. With NCATS, the NIH will invest tax payer dollars in the riskiest ‘precompetitive’ stages of drug discovery. NCATS has also articulated a commitment to bring to...
متن کاملRisky business.
Risky Business iii Acknowledgments ConnectEd: The California Center for College and Career and The National Consortium on Health Science and Technology Education (NCHSTE) want to thank the many people who supported this work and helped develop these integrated curriculum units. We would especially like to thank the academic and health science teachers from 12 high schools who participated in ou...
متن کاملB-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
PURPOSE Multiple myeloma is a usually incurable malignancy of plasma cells. New therapies are urgently needed for multiple myeloma. Adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a promising new therapy for hematologic malignancies, but an ideal target antigen for CAR-expressing T-cell therapies for multiple myeloma has not been identified. B-cell maturation antigen ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2013
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2013-09-527622